Situation Inference for Mobile Users: a Rule Based Approach

Mobile phones are being increasingly equipped with sensors that ease retrieval of context information about a user. Context data can be aggregated with information centrally available to mobile operators and service providers, to infer higher-level information such as user “situations”, easier to integrate with services. We have been conducting an internal trial monitoring the context of different users in their business life and designing rules to infer high level situations: logical location, activity and social state. In this paper we present the infrastructure and the rulebased reasoning process used for this experiment

Enhancing Children’s Experience with Recommendation Systems

Recommender Systems (RSs) offer a personalized support in exploring large amounts of information, assisting users in decision making about products matching their taste and preferences. Most of the research todate on recommender systems have focused on traditional users, i.e., adult individuals who are able to offer explicit feedback, write reviews, or purchase items themselves. However, children's patterns of attention and interaction are quite different from those of adults. This paper presents the first results of a research-in-progress that can be suited to bridge the barrier between children and a recom-mender system by providing a child-friendly interaction paradigm. Specifically, a web application is developed that employs real-time object recognition on movie thumbnails or DVD cover-photos in a real-time manner. The tangible object can be manipulated by the user and provide input to the system for the purpose of generating movie recommendations. We plan to extend this work to the scenario where the child could ask for a video content showing a related toy (e.g., a car, a plane, the doll of a character that she likes in a cartoon) and the system could generate the videos that matches these implicit preferences expressed by the chil

Etiology, management, and outcome of the Budd-Chiari syndrome

Background: The Budd-Chiari syndrome (BCS) is hepatic venous outflow obstruction. What is known about the syndrome is based on small studies of prevalent cases. Objective: To characterize the causes and treatment of incident BCS. Design: Consecutive case series of patients with incident BCS, enrolled from October 2003 to October 2005 and followed until May 2006. Setting: Academic and nonacademic hospitals in France, Spain, Italy, Great Britain, Germany, Belgium, the Netherlands, Portugal, and Switzerland. Patients: Persons older than 16 years with definite hepatic outflow obstruction diagnosed by imaging. Persons with hepatic outflow obstruction due to heart failure, sinusoidal obstruction syndrome, cancer, or liver transplantation were excluded. Measurements: Signs and symptoms; laboratory and imaging findings; diagnosis; treatment; and overall, transplantation-free, and intervention-free survival. Results: 163 incident cases of BCS were identified. Median follow-up was 17 months (range, 0.1 to 31 months). Most patients (84%) had at least 1 thrombotic risk factor, and many (46%) had more than 1; the most common was myeloproliferative disorders (49% of 103 tested patients). Patients were mainly treated with anticoagulation (140 patients [86%]), transjugular intrahepatic portosystemic shunting (56 patients [34%]), or liver transplantation (20 patients [12%]), and 80 patients (49%) were managed noninvasively. Only 3 patients underwent surgical shunting. The survival rate was 87% (95% CI, 82% to 93%) at 1 year and 82% (CI, 75% to 88%) at 2 years. Limitation: Treatment was not standardized across all centers, and data on important clinical variables were missing for some patients. Conclusion: Most patients with BCS have at least 1 thrombotic risk factor, and many have more than 1; myeloproliferative disorders are most common. One- and 2-year survival rates are good with contemporary management, which includes noninvasive therapies (anticoagulation and diuretics) and invasive techniques. Transjugular intrahepatic portosystemic shunting seems to have replaced surgical shunting as the most common invasive therapeutic procedure. Primary Funding Source: Fifth Framework Programme of the European Commission

Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis

Carta a l'editorWe studied the role of the recently identified CALR mutations in 141 patients with Budd-Chiari Syndrome (BCS) or portal vein thrombosis (PVT) in a large multinational cohort. A CALR mutation was present in one of the 141 patients (0.7%). This patient was previously diagnosed with primary myelofibrosis. This results in CALR positivity in one out of 44 (2.3%) patients with myeloproliferative neoplasm (MPN), and in one of 11 (9.1%) JAK2V617F negative patients diagnosed with MPN. We suggest that analysis of CALR mutations should be performed in JAK2V617F negative BCS and PVT patients..

3cixty: Building comprehensive knowledge bases for city exploration

International audiencePlanning a visit to Expo Milano 2015 or simply touring in Milan are activities that require a certain amount of a priori knowledge of the city. In this paper, we present the process of building such comprehensive knowledge bases that contain descriptions of events and activities, places and sights, transportation facilities as well as social activities, collected from numerous static, near-and real-time local and global data providers, including hyper local sources such as the Expo Milano 2015 official services and several social media platforms. Entities in the 3cixty KB are deduplicated, interlinked and enriched using semantic technologies. The 3cixty KB is empowering the ExplorMI 360 multi-device application, which has been officially endorsed by the E015 Technical Management Board and has gained the patronage of Expo Milano in 2015, thus has offered a unique testing scenario for the 20 million visitors along the 6 months of the exhibit. In 2016-2017, new knowledge bases have been created for the cities of London, Madeira and Singapore, as well as for the entire French Cote d'Azur area. The 3cixty KB is accessible at https: //kb.3cixty.com/sparql while ExplorMI 360 at https://www.3cixty.com and in the Google Play Store and Apple App Store

3cixty@Expo Milano 2015: Enabling Visitors to Explore a Smart City

-Planning a visit to Expo Milano 2015 or simply touring in Milan are activities that require a certain amount of a priori knowledge of the city. In this paper, we present the process of building such a comprehensive knowledge base, the 3cixty KB, that contains descriptions of events, places, transportation facilities and social activities, collected from numerous static, near-and real-time local and global data providers, including Expo Milano 2015 official services and several social media platforms. Entities in the 3cixty KB are deduplicated, interlinked and enriched using semantic technologies. The 3cixty KB is empowering the Ex-plorMI 360 multi-device application, which has been officially endorsed by the E015 Technical Management Board and has gained the patronage of Expo Milano 2015, thus offering a unique testing scenario for the 20 million expected visitors along the 6 months of the exhibit. As of Septem-ber 7th, 2015 the 3cixty KB contains unique descriptions of 18, 665 events, 758 artists, 225, 552 places, 9, 342 transportation facilities, 95, 570 illustrating photos and 94, 789 reviews contributed by 81, 944 users. The 3cixty KB is accessible at http://3cixty.eurecom.fr/sparql while Ex-plorMI 360 at https://www.3cixty.com

Congenital extrahepatic portosystemic shunts (Abernethy malformation): An international observational study

Congenital extrahepatic portosystemic shunt (CEPS) or Abernethy malformation is a rare condition in which splanchnic venous blood bypasses the liver draining directly into systemic circulation through a congenital shunt. Patients may develop hepatic encephalopathy (HE), pulmonary hypertension (PaHT), or liver tumors, among other complications. However, the actual incidence of such complications is unknown, mainly because of the lack of a protocolized approach to these patients. This study characterizes the clinical manifestations and outcome of a large cohort of CEPS patients with the aim of proposing a guide for their management. This is an observational, multicenter, international study. Sixty-six patients were included; median age at the end of follow-up was 30 years. Nineteen patients (28%) presented HE. Ten-, 20-, and 30-year HE incidence rates were 13%, 24%, and 28%, respectively. No clinical factors predicted HE. Twenty-five patients had benign nodular lesions. Ten patients developed adenomas (median age, 18 years), and another 8 developed HCC (median age, 39 years). Of 10 patients with dyspnea, PaHT was diagnosed in 8 and hepatopulmonary syndrome in 2. Pulmonary complications were only screened for in 19 asymptomatic patients, and PaHT was identified in 2. Six patients underwent liver transplantation for hepatocellular carcinoma or adenoma. Shunt closure was performed in 15 patients with improvement/stability/cure of CEPS manifestations. Conclusion: CEPS patients may develop severe complications. Screening for asymptomatic complications and close surveillance is needed. Shunt closure should be considered both as a therapeutic and prophylactic approach

ITALIAN CANCER FIGURES - REPORT 2015: The burden of rare cancers in Italy = I TUMORI IN ITALIA - RAPPORTO 2015: I tumori rari in Italia

OBJECTIVES: This collaborative study, based on data collected by the network of Italian Cancer Registries (AIRTUM), describes the burden of rare cancers in Italy. Estimated number of new rare cancer cases yearly diagnosed (incidence), proportion of patients alive after diagnosis (survival), and estimated number of people still alive after a new cancer diagnosis (prevalence) are provided for about 200 different cancer entities. MATERIALS AND METHODS: Data herein presented were provided by AIRTUM population- based cancer registries (CRs), covering nowadays 52% of the Italian population. This monograph uses the AIRTUM database (January 2015), which includes all malignant cancer cases diagnosed between 1976 and 2010. All cases are coded according to the International Classification of Diseases for Oncology (ICD-O-3). Data underwent standard quality checks (described in the AIRTUM data management protocol) and were checked against rare-cancer specific quality indicators proposed and published by RARECARE and HAEMACARE (www.rarecarenet.eu; www.haemacare.eu). The definition and list of rare cancers proposed by the RARECAREnet "Information Network on Rare Cancers" project were adopted: rare cancers are entities (defined as a combination of topographical and morphological codes of the ICD-O-3) having an incidence rate of less than 6 per 100,000 per year in the European population. This monograph presents 198 rare cancers grouped in 14 major groups. Crude incidence rates were estimated as the number of all new cancers occurring in 2000-2010 divided by the overall population at risk, for males and females (also for gender-specific tumours).The proportion of rare cancers out of the total cancers (rare and common) by site was also calculated. Incidence rates by sex and age are reported. The expected number of new cases in 2015 in Italy was estimated assuming the incidence in Italy to be the same as in the AIRTUM area. One- and 5-year relative survival estimates of cases aged 0-99 years diagnosed between 2000 and 2008 in the AIRTUM database, and followed up to 31 December 2009, were calculated using complete cohort survival analysis. To estimate the observed prevalence in Italy, incidence and follow-up data from 11 CRs for the period 1992-2006 were used, with a prevalence index date of 1 January 2007. Observed prevalence in the general population was disentangled by time prior to the reference date (≤2 years, 2-5 years, ≤15 years). To calculate the complete prevalence proportion at 1 January 2007 in Italy, the 15-year observed prevalence was corrected by the completeness index, in order to account for those cancer survivors diagnosed before the cancer registry activity started. The completeness index by cancer and age was obtained by means of statistical regression models, using incidence and survival data available in the European RARECAREnet data. RESULTS: In total, 339,403 tumours were included in the incidence analysis. The annual incidence rate (IR) of all 198 rare cancers in the period 2000-2010 was 147 per 100,000 per year, corresponding to about 89,000 new diagnoses in Italy each year, accounting for 25% of all cancer. Five cancers, rare at European level, were not rare in Italy because their IR was higher than 6 per 100,000; these tumours were: diffuse large B-cell lymphoma and squamous cell carcinoma of larynx (whose IRs in Italy were 7 per 100,000), multiple myeloma (IR: 8 per 100,000), hepatocellular carcinoma (IR: 9 per 100,000) and carcinoma of thyroid gland (IR: 14 per 100,000). Among the remaining 193 rare cancers, more than two thirds (No. 139) had an annual IR <0.5 per 100,000, accounting for about 7,100 new cancers cases; for 25 cancer types, the IR ranged between 0.5 and 1 per 100,000, accounting for about 10,000 new diagnoses; while for 29 cancer types the IR was between 1 and 6 per 100,000, accounting for about 41,000 new cancer cases. Among all rare cancers diagnosed in Italy, 7% were rare haematological diseases (IR: 41 per 100,000), 18% were solid rare cancers. Among the latter, the rare epithelial tumours of the digestive system were the most common (23%, IR: 26 per 100,000), followed by epithelial tumours of head and neck (17%, IR: 19) and rare cancers of the female genital system (17%, IR: 17), endocrine tumours (13% including thyroid carcinomas and less than 1% with an IR of 0.4 excluding thyroid carcinomas), sarcomas (8%, IR: 9 per 100,000), central nervous system tumours and rare epithelial tumours of the thoracic cavity (5%with an IR equal to 6 and 5 per 100,000, respectively). The remaining (rare male genital tumours, IR: 4 per 100,000; tumours of eye, IR: 0.7 per 100,000; neuroendocrine tumours, IR: 4 per 100,000; embryonal tumours, IR: 0.4 per 100,000; rare skin tumours and malignant melanoma of mucosae, IR: 0.8 per 100,000) each constituted <4% of all solid rare cancers. Patients with rare cancers were on average younger than those with common cancers. Essentially, all childhood cancers were rare, while after age 40 years, the common cancers (breast, prostate, colon, rectum, and lung) became increasingly more frequent. For 254,821 rare cancers diagnosed in 2000-2008, 5-year RS was on average 55%, lower than the corresponding figures for patients with common cancers (68%). RS was lower for rare cancers than for common cancers at 1 year and continued to diverge up to 3 years, while the gap remained constant from 3 to 5 years after diagnosis. For rare and common cancers, survival decreased with increasing age. Five-year RS was similar and high for both rare and common cancers up to 54 years; it decreased with age, especially after 54 years, with the elderly (75+ years) having a 37% and 20% lower survival than those aged 55-64 years for rare and common cancers, respectively. We estimated that about 900,000 people were alive in Italy with a previous diagnosis of a rare cancer in 2010 (prevalence). The highest prevalence was observed for rare haematological diseases (278 per 100,000) and rare tumours of the female genital system (265 per 100,000). Very low prevalence (<10 prt 100,000) was observed for rare epithelial skin cancers, for rare epithelial tumours of the digestive system and rare epithelial tumours of the thoracic cavity. COMMENTS: One in four cancers cases diagnosed in Italy is a rare cancer, in agreement with estimates of 24% calculated in Europe overall. In Italy, the group of all rare cancers combined, include 5 cancer types with an IR>6 per 100,000 in Italy, in particular thyroid cancer (IR: 14 per 100,000).The exclusion of thyroid carcinoma from rare cancers reduces the proportion of them in Italy in 2010 to 22%. Differences in incidence across population can be due to the different distribution of risk factors (whether environmental, lifestyle, occupational, or genetic), heterogeneous diagnostic intensity activity, as well as different diagnostic capacity; moreover heterogeneity in accuracy of registration may determine some minor differences in the account of rare cancers. Rare cancers had worse prognosis than common cancers at 1, 3, and 5 years from diagnosis. Differences between rare and common cancers were small 1 year after diagnosis, but survival for rare cancers declined more markedly thereafter, consistent with the idea that treatments for rare cancers are less effective than those for common cancers. However, differences in stage at diagnosis could not be excluded, as 1- and 3-year RS for rare cancers was lower than the corresponding figures for common cancers. Moreover, rare cancers include many cancer entities with a bad prognosis (5-year RS <50%): cancer of head and neck, oesophagus, small intestine, ovary, brain, biliary tract, liver, pleura, multiple myeloma, acute myeloid and lymphatic leukaemia; in contrast, most common cancer cases are breast, prostate, and colorectal cancers, which have a good prognosis. The high prevalence observed for rare haematological diseases and rare tumours of the female genital system is due to their high incidence (the majority of haematological diseases are rare and gynaecological cancers added up to fairly high incidence rates) and relatively good prognosis. The low prevalence of rare epithelial tumours of the digestive system was due to the low survival rates of the majority of tumours included in this group (oesophagus, stomach, small intestine, pancreas, and liver), regardless of the high incidence rate of rare epithelial cancers of these sites. This AIRTUM study confirms that rare cancers are a major public health problem in Italy and provides quantitative estimations, for the first time in Italy, to a problem long known to exist. This monograph provides detailed epidemiologic indicators for almost 200 rare cancers, the majority of which (72%) are very rare (IR<0.5 per 100,000). These data are of major interest for different stakeholders. Health care planners can find useful information herein to properly plan and think of how to reorganise health care services. Researchers now have numbers to design clinical trials considering alternative study designs and statistical approaches. Population-based cancer registries with good quality data are the best source of information to describe the rare cancer burden in a population

Using Adaptive Rate Estimation to Provide Enhanced and Robust Transport over Heterogeneous Networks

The rapid advancement in wireless communication technology has spurred significant interest in the design and development of enhanced TCP protocols. Among them, TCP Westwood (TCPW) is a sender side only modification to improve TCP performance particularly over heterogeneous networks. The key idea of TCPW is to use rate estimation methods to set the congestion window and slow start threshold after a packet loss. When packet losses are not only due to buffer overflow, but random errors as well, TCPW estimation methods have been shown to provide significant performance improvement. The earliest estimation method, called Bandwidth Estimation (BE), however, may result in over-estimation under certain circumstances, and thus may be unfriendly toward non-TCPW traffic. TCPW CRB (Combined Rate and Bandwidth estimation) and TCPW ABSE (Adaptive Bandwidth Share Estimation), have been later introduced to address this concern. The schemes provide better control of the tradeoffs among efficiency, friendliness, and implementation complexity. CRB may slightly sacrifice the efficiency gain to ensure friendliness. ABSE adaptivity mechanisms are more sophisticated and provide both better efficiency and friendliness. In this paper, we summarize ABSE, which adapts to congestion level, as well as round drip time, and other network dynamics, thus providing enhanced and robust performance under various network conditions. Extensive experiments show that TCPW ABSE is able to enhance TCP performance significantly over "large leaky pipes", while maintaining friendliness toward TCP NewReno. In this paper we show that TCPW ABSE is robust to packet and ACK compression due to cross traffic on forward and backward paths. We also show that ABSE is robust to buffer size variations, which are inevitable i..

Letting Users Assist What to Watch: An Interactive Query-by-Example Movie Recommendation System

In this article we propose an interactive Web-based movie recommendation system namely MISRec employing object recognition for movie thumbnails. The proposed system carries out object recognition on movie thumbnails or DVD cover-photos in a real-time manner, and recommends movies based on user’s historical preferences and the query intention. Unlike typical preference-based recommendation systems which provide recommendations merely by using the user’s historical preference, MISRec provides a user with a choice to specify her search intention in a user-friendly and interactive manner and to alter/adjust the recommendation results which in turn can lead to increased utility of recommendation and user satisfaction